SolarWinds, Inc. (NYSE:SWI) shares moved down -1.19% in last trading session and ended the day at $58.00. SWI Gross Margin is 89.20% and its has a return on assets of 10.70%. SolarWinds, Inc. (NYSE:SWI) quarterly performance is 17.22%.
SolarWinds, Inc. (NYSE:SWI) reported preliminary 2015 net income of $95.3 million compared with $78.1 million the previous year. The Austin software maker that last week approved a $4.5 billion buyout also reported full-year revenue of $504.1 million, a 17.6 rise versus revenue of $428.7 million in 2014, according to a filing with the U.S. Securities and Exchange Commission.
The Procter & Gamble Company (NYSE:PG) ended the last trading day at $75.83. Company weekly volatility is calculated as 1.68% and price to cash ratio as 16.37. The Procter & Gamble Company (NYSE:PG) showed a weekly performance of -0.89%.
The Procter & Gamble Company (NYSE:PG) announced that it would begin trading ex-dividend on January 20. Moreover, a cash dividend payment of $0.663 per share is scheduled to be paid on February 16.
On 20 January, Retail Opportunity Investments Corp. (NASDAQ:ROIC) shares moved down -1.02% and was closed at $17.45. ROIC EPS growth in last 5 year was 26.30%. Retail Opportunity Investments Corp. (NASDAQ:ROIC) year to date (YTD) performance is -2.51%.
On 7 Jnauary, Retail Opportunity Investments Corp. (NASDAQ:ROIC) announced that during 2015 the company completed a total of $479.5 million of grocery-anchored shopping center acquisitions, encompassing approximately 1.3 million square feet.
Rubicon Technology, Inc. (NASDAQ:RBCN) shares moved down -8.74% in last trading session and ended the day at $0.94. RBCN Gross Margin is -64.70% and its has a return on assets of -43.40%. Rubicon Technology, Inc. (NASDAQ:RBCN) quarterly performance is -27.13%.
Calithera Biosciences, Inc. (NASDAQ:CALA) caters to the Healthcare space. Its weekly performance is -7.25%. On the last day of trading company shares ended up at $5.37. Calithera Biosciences, Inc. (NASDAQ:CALA) distance from 50-day simple moving average (SMA50) is -18.60%.
Zacks Investment Research cut shares of Calithera Biosciences Inc (NASDAQ:CALA) from a buy rating to a hold rating in a research report published on Tuesday, Analyst Ratings.Net reports.
Leave a Reply